ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: The study found that JAK2 and JAK3 had antiproliferative effects on imatinib-resistant BCR-ABL(+) cells [41], and the administration of imatinib plus a JAK inhibitor reduced expression of stem cells markers, enhancing the antitumour effects of imatinib in CML cells [42].